PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
R&D reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive risk.
-16.18%
G&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses change of 7.12% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
-22.68%
Operating expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine advantage.
-22.68%
Total costs reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A change of 7.12% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
22.73%
EBITDA change of 22.73% while RVPH is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Income change of 22.68% while RVPH is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses change of 26.92% while RVPH maintains costs. Bruce Berkowitz would investigate control.
22.99%
Income change of 22.99% while RVPH is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% while RVPH maintains burden. Bruce Berkowitz would investigate strategy.
22.99%
Income change of 22.99% while RVPH is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS change of 38.32% while RVPH is flat. Bruce Berkowitz would examine quality.
38.32%
Diluted EPS change of 38.32% while RVPH is flat. Bruce Berkowitz would examine quality.
24.80%
Share count change of 24.80% while RVPH is stable. Bruce Berkowitz would verify approach.
24.80%
Diluted share change of 24.80% while RVPH is stable. Bruce Berkowitz would verify approach.